Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
alt text
sign up
C4X Discovery Holdings plc
Company Name:C4X Discovery Holdings plc Minimum fundraise:£0.00* High Share Price Bid:£0.00
Business Sector:Pharmaceuticals, healthcare and biotechnology Total Funds Bid to Date:£0.00 Low Share Price Bid:£0.00
Auction period:26 Apr 2024 - 13 Jun 2024 Indicative Share Price:0.00 Average Share Price Bid:£0.00**
Company Details Below
*The company will accept oversubscription.
**In the event of significant oversubscription, shares will be allocated to bids at the average price and above.
NOTE: ASSET MATCH HAS NEGOTIATED AN “ASSET MATCH INVESTOR BONUS” FOR INVESTORS IN THIS TRANSACTION. SEE THE “OVERVIEW” SECTION BELOW FOR DETAILS.

Need help?
+44 (0) 207 248 2788

back

C4X Discovery Holdings plc

C4X Discovery Holdings plc

Market Cap: £30,267,252 Auction period: 26 Apr 2024 - 13 Jun 2024 Indicative price: 0.00

Live Started 20 days ago

Lowest Offer 12.00p

Auction closes in 27 days


BUY ORDERS SELL ORDERS

BuyersShares Wanted Total Wanted Share Price (p)
-- -- -- 12.00
       
Share Price (p) Total Offered Shares OfferedSellers
12.00 25,928 25,928 2
       

BUY ORDERS

SELL ORDERS

Buyers Shares Total Shares Share Price (p) Total Shares Shares Sellers
-- -- -- 12.00 25,928 25,928 2
             

Interested in C4X Discovery Holdings plc?
Register or log in to participate, create a watchlist, or set reminder

Register Log in

Company info

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. Our internal portfolio of discovery programmes is advancing towards clinical trials with one programme in the pre-clinical candidate selection stage. We have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.

www.c4xdiscovery.com

Auction Details

The Ordinary Shares of C4X Discovery Holdings plc were admitted to trading on Asset Match on 26 April 2024 at a price of 12 pence per share (being the last traded price on AIM).

Auctions are to be held quarterly and close at 4pm on the second Thursday of each month (unless stated otherwise).

The tick size for this company is 0.5 pence per share.

Participants can send orders via their existing broker or directly to shareDeal active. Further details can be found by clicking on the "Auction instructions" section below.

Auction instructions

To buy and sell shares in this company via Asset Match Private Market, you will need to use a stockbroker.

           -  shareDeal active

If you are a UK resident, our main broker and settlement agent for all CREST eligible companies on the AM Private Market is shareDeal active.

shareDeal active provide a competitively priced service for both certified and non-certified transactions. You can open an account online or by post using the form provided.

Alternatively, if you already have an account with shareDeal active and wish to place an order please contact the Dealing desk directly on 01892 510515 or deal online.

To sell a share certificate, the easiest way to trade is to set up a shareDeal active account online and once open post your share certificate with a completed CREST transfer form. Alternatively, you can open an account by post using the Asset Match Certificated Sale Pack which includes everything you will need.

It generally takes 5-7 days for your account to be open and shares available for trading.

           -  Already have a stockbroker

Over 60 UK brokers regularly trade and are set up to deal on our platform. These brokers can submit your instructions to shareDeal active on your behalf*.

Please note that not all brokers are able to deal in unquoted shares so contact us to confirm whether your broker is able to trade.

           -  Overseas

If you are based overseas and are interested in participating then please contact us directly by emailing dealing@assetmatch.com or by calling 020 7248 2788.

​​When buying and selling shares, please note that the Asset Match levy of 3% applies, with a minimum charge of £20 per trade (*additional fees may apply).

For more information on how the auction works then please click here.

 

Key People

Clive

Clive Dix PHD Executive Chair

Clive has more than 30 years’ experience through senior pharmaceutical industry positions and a degree and PhD in Pharmacology. His expertise includes an in-depth understanding of Drug Discovery and development, a broad knowledge of the science and commercial landscape across therapeutic areas and solid experience of the pharmaceutical business and finance community supporting the sector. Clive was Co-Founder and CEO of Convergence Pharmaceuticals Ltd, acquired by Biogen, and Co-Founder and CEO of PowderMed Ltd, acquired by Pfizer. Previously, he was SVP, Research and Development and a Board member of PowderJect Pharmaceuticals plc, acquired by Chiron Vaccines. Clive began his career in industry at Ciba-Geigy and GlaxoWellcome. Clive is currently on the Board of PHTA, the University of Birmingham’s flagship research facility and Non-Executive Chairman of Kesmalea Therapeutics. He was Chairman of the BioIndustry Association and interim Chair of the UK Vaccines taskforce who oversaw the supply of one of the most successful COVID-19 vaccine rollout programmes in the world.
   
Brad

Brad Hoy Chief Financial Officer

Brad has more than 20 years’ experience in the pharmaceutical and biotechnology industries and has held a number of senior financial and general management positions in both the UK and the US. Previously, Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed specialty pharmaceutical company, Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company, and Senior Director of Geron Corporation’s stem cell-focused UK subsidiary. Brad was formerly a Non-Executive Director on the Board of Directors for e-Therapeutics plc.
   
Bhuvna

Bhuvna Hunjan Chief Business Officer

Bhavna has spent almost 15 years in commercial and corporate roles, first as an investment banker at Lehman Brothers and Nomura International and then in corporate strategy at PwC and Cancer Research UK. In 2016, she was hired by C4XD to incept and establish a new team focused on business development, deal structuring and execution, commercial intelligence, financing, and strategic planning / M&A. Since then, Bhavna has led this team to execute a series of successful licensing deals and strategic partnerships, as well as driving business growth and capital raising as part of the Executive Management team. Bhavna has a first class Masters degree in Biochemistry from the University of Oxford. She was awarded a Rising Star in the Movers & Shakers in BioBusiness 2017, and also voted one of the 30 Rising Leaders in Life Sciences 2020 by In Vivo.
   
Simon

Simon Harford Non-Executive Director

Simon’s career spans more than 35 years with significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Amicus Therapeutics, a NASDAQ-listed rare disease biotech and was previously CFO of Albireo Pharma Inc. a rare paediatric liver disease biotech until its sale to Ipsen. Prior to this, he was CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Simon spent almost three decades in the pharmaceutical industry holding various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman’s Ovation Award 2004 for outstanding achievement to Lilly. Simon has an MBA from the Darden School of Business at the University of Virginia.
   
Alex

Alex Stephenson PHD Non-Executive Director

Alex began his career as a microbiologist, working in research for a number of years before joining an NYSE-quoted drug development company. He subsequently moved into pharmaceutical and healthcare investment and has fulfilled a number of board-level investment and operational management roles. He was a Director and shareholder in Aquarius Equity from 2008, where he was responsible for identifying new investments and developing and implementing scientific strategies both pre and post-investment. These included Tissue Regenix Group plc, C4X Discovery Holdings plc and Brabant Pharma (subsequently sold to Zogenix, Inc.). Alex joined the Board of C4XD as a Non-Executive Director following Aquarius’ investment in the Company.
   
Natalie

Natalie Walter Non-Executive Director

Natalie is a corporate finance lawyer with more than 20 years of experience advising on international equity capital markets transactions in the healthcare sector. Natalie is currently General Counsel to Oxford Biomedica plc, a FTSE 250 gene and cell therapy company. Prior to joining Oxford Biomedica, Natalie was an Equity Partner at Covington & Burling LLP advising Boards on a range of strategic, transactional and general corporate finance matters, with particular expertise in advising on deals in the life sciences sector. Prior to this, Natalie had been an Equity Partner at Morrison & Foerster LLP and had spent part of her career as a Director and Legal Counsel on the ECM desk at Lehman Brothers. Natalie was a Board member of RSA (Holdings) Limited until March 2020.